AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

NASDAQ:AXSM • US05464T1043

164.1 USD
+0.91 (+0.56%)
Last: Feb 27, 2026, 10:12 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall AXSM gets a fundamental rating of 3 out of 10. We evaluated AXSM against 192 industry peers in the Pharmaceuticals industry. AXSM has a bad profitability rating. Also its financial health evaluation is rather negative. AXSM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year AXSM has reported negative net income.
  • AXSM had a negative operating cash flow in the past year.
  • In the past 5 years AXSM always reported negative net income.
  • In the past 5 years AXSM always reported negative operating cash flow.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • AXSM has a Return On Assets (-34.31%) which is in line with its industry peers.
  • With a Return On Equity value of -311.44%, AXSM is not doing good in the industry: 75.52% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -34.31%
ROE -311.44%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

1.3 Margins

  • AXSM's Gross Margin of 91.86% is amongst the best of the industry. AXSM outperforms 93.75% of its industry peers.
  • AXSM's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.09%
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AXSM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • AXSM has an Altman-Z score of 5.76. This indicates that AXSM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.76, AXSM is in the better half of the industry, outperforming 77.60% of the companies in the same industry.
  • AXSM has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of AXSM (2.61) is worse than 79.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Altman-Z 5.76
ROIC/WACCN/A
WACC9.32%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.57 indicates that AXSM should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.57, AXSM is doing worse than 69.79% of the companies in the same industry.
  • A Quick Ratio of 1.50 indicates that AXSM should not have too much problems paying its short term obligations.
  • AXSM has a worse Quick ratio (1.50) than 60.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.5
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 38.40% over the past year.
  • Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 65.55%.
  • Measured over the past years, AXSM shows a very strong growth in Revenue. The Revenue has been growing by 133.68% on average per year.
EPS 1Y (TTM)38.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.64%
Revenue 1Y (TTM)65.55%
Revenue growth 3Y133.68%
Revenue growth 5YN/A
Sales Q2Q%65.03%

3.2 Future

  • AXSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.59% yearly.
  • Based on estimates for the next years, AXSM will show a very strong growth in Revenue. The Revenue will grow by 37.27% on average per year.
EPS Next Y122.19%
EPS Next 2Y111.7%
EPS Next 3Y75.72%
EPS Next 5Y55.59%
Revenue Next Year58.77%
Revenue Next 2Y56.56%
Revenue Next 3Y47.15%
Revenue Next 5Y37.27%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 200.38, the valuation of AXSM can be described as expensive.
  • 68.23% of the companies in the same industry are more expensive than AXSM, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of AXSM to the average of the S&P500 Index (28.13), we can say AXSM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 200.38
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • AXSM's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AXSM's earnings are expected to grow with 75.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y111.7%
EPS Next 3Y75.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (2/27/2026, 10:12:14 AM)

164.1

+0.91 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-23
Earnings (Next)05-04
Inst Owners75.2%
Inst Owner Change-0.38%
Ins Owners1.13%
Ins Owner Change-1.23%
Market Cap8.27B
Revenue(TTM)638.50M
Net Income(TTM)-229.62M
Analysts85.38
Price Target223.66 (36.29%)
Short Float %6.49%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.42%
Min EPS beat(2)-6.47%
Max EPS beat(2)13.31%
EPS beat(4)2
Avg EPS beat(4)-8.01%
Min EPS beat(4)-48.67%
Max EPS beat(4)13.31%
EPS beat(8)3
Avg EPS beat(8)-17.43%
EPS beat(12)4
Avg EPS beat(12)-9.71%
EPS beat(16)7
Avg EPS beat(16)-5.43%
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.13%
Max Revenue beat(2)6.01%
Revenue beat(4)2
Avg Revenue beat(4)1.86%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)6.01%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)9
Avg Revenue beat(12)24.39%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.79%
PT rev (3m)19.2%
EPS NQ rev (1m)5.43%
EPS NQ rev (3m)7.86%
EPS NY rev (1m)-1.63%
EPS NY rev (3m)-2.88%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)3.06%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)2.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 200.38
P/S 14.74
P/FCF N/A
P/OCF N/A
P/B 112.2
P/tB 422.94
EV/EBITDA N/A
EPS(TTM)-3.69
EYN/A
EPS(NY)0.82
Fwd EY0.5%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS11.13
BVpS1.46
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.31%
ROE -311.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.86%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.09%
GM growth 5YN/A
F-Score5
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.95%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.5
Altman-Z 5.76
F-Score5
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.64%
EPS Next Y122.19%
EPS Next 2Y111.7%
EPS Next 3Y75.72%
EPS Next 5Y55.59%
Revenue 1Y (TTM)65.55%
Revenue growth 3Y133.68%
Revenue growth 5YN/A
Sales Q2Q%65.03%
Revenue Next Year58.77%
Revenue Next 2Y56.56%
Revenue Next 3Y47.15%
Revenue Next 5Y37.27%
EBIT growth 1Y29.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.56%
EBIT Next 3Y90.14%
EBIT Next 5Y56.34%
FCF growth 1Y23.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.88%
OCF growth 3YN/A
OCF growth 5YN/A

AXSOME THERAPEUTICS INC / AXSM FAQ

What is the fundamental rating for AXSM stock?

ChartMill assigns a fundamental rating of 3 / 10 to AXSM.


Can you provide the valuation status for AXSOME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 2 / 10 to AXSOME THERAPEUTICS INC (AXSM). This can be considered as Overvalued.


How profitable is AXSOME THERAPEUTICS INC (AXSM) stock?

AXSOME THERAPEUTICS INC (AXSM) has a profitability rating of 1 / 10.


Can you provide the financial health for AXSM stock?

The financial health rating of AXSOME THERAPEUTICS INC (AXSM) is 3 / 10.


What is the earnings growth outlook for AXSOME THERAPEUTICS INC?

The Earnings per Share (EPS) of AXSOME THERAPEUTICS INC (AXSM) is expected to grow by 122.19% in the next year.